Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | GNRHR | P30968 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447689 | 1.00 | KDM4E (0.57) | KDM4EPKMGNRHRACKR3MAPK8 | |
| SCHEMBL4592808 | 0.83 | HPGD (0.52) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4592805 | 0.83 | HPGD (0.52) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL13326532 | 0.83 | KDM4E (0.60) | KDM4EPKMGNRHRACKR3NAMPT | |
| SCHEMBL14731327 | 0.83 | KDM4E (0.69) | KDM4EPKMACKR3IDO1TDO2 | |
| SCHEMBL3449150 | 0.81 | ACKR3 (0.66) | KDM4EPKMGNRHRACKR3IDO1 | |
| SCHEMBL4592230 | 0.81 | ACKR3 (0.66) | KDM4EPKMGNRHRACKR3IDO1 | |
| SCHEMBL3449148 | 0.81 | ACKR3 (0.66) | KDM4EPKMGNRHRACKR3IDO1 | |
| SCHEMBL18988022 | 0.79 | USP30 (0.64) | KDM4EPKMGNRHRACKR3NAMPT | |
| SCHEMBL30624634 | 0.78 | FPR2 (0.49) | KDM4EPKMIDO1TDO2FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | KDM4E 2242/4885PKM 1858/4885GNRHR 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.